Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry

BACKGROUND: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A., Miletello, G. P., Curti, B., Agarwal, Neeraj, Hauke, R., Mahoney, K. M., Moon, H., Treisman, J., Tykodi, S. S., Daniels, G., Morse, M. A., Wong, M. K. K., Kaufman, H., Gregory, N., McDermott, D. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437874/
https://www.ncbi.nlm.nih.gov/pubmed/30917871
http://dx.doi.org/10.1186/s40425-019-0567-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437874/
https://www.ncbi.nlm.nih.gov/pubmed/30917871
http://dx.doi.org/10.1186/s40425-019-0567-3

Ejemplares similares